Y. Nakaya

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

T. Niwa, K. Shimoda, K. Shide, 2011, Blood cancer journal.

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis

T. Niwa, K. Shimoda, K. Shide, 2014, Blood Cancer Journal.

NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients.

M. Taniwaki, J. Kuroda, Ayumi Kodama, 2014, Leukemia research.

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.

S. Kimura, K. Hirabayashi, S. Ito, 2006, Leukemia research.

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

Tomoko Niwa, Takeshi Yuasa, Eri Kawata, 2005, Blood.

Multimodal tangential migration of neocortical GABAergic neurons independent of GPI-anchored proteins

Y. Yanagawa, K. Obata, F. Murakami, 2003, Development.